The pathophysiology of ocular allergy: current thinking

Area of Science:

• Ophthalmology
• Immunology
• Allergy Research

Background:

• Seasonal allergic conjunctivitis is unique in its sole reliance on Type-1 hypersensitivity.
• Other ocular allergies involve complex immunology and chronic inflammation, potentially causing severe corneal damage.
• Effective management requires controlling inflammation while minimizing steroid side effects and promoting allergen avoidance.

Purpose of the Study:

• To evaluate the efficacy of anti-inflammatory drugs in a relevant animal model of allergic conjunctivitis.
• To assess the potential of second-generation mast cell stabilizers in treating ocular allergy.

Main Methods:

• Utilized SWR mice, topically sensitized and challenged with short ragweed, to model human allergic conjunctivitis pathophysiology.
• Observed clinical signs, mast cell, and eosinophil involvement in the animal model.
• Assessed the anti-inflammatory activity of steroids and nedocromil sodium.

Main Results:

• The SWR mouse model demonstrated clinical signs and inflammatory cell involvement similar to human allergic conjunctivitis.
• Both steroids and nedocromil sodium exhibited significant anti-inflammatory activity in this model.
• The study supports the therapeutic use of nedocromil sodium, a second-generation mast cell stabilizer.

Conclusions:

• The SWR mouse model is a valuable tool for studying allergic conjunctivitis and evaluating potential treatments.
• Second-generation mast cell stabilizing drugs, like nedocromil sodium, show promise in managing ocular allergy.
• Controlling ocular inflammation effectively is crucial for preventing vision-threatening complications.